Probiodrug Ges. für Arzneimittelforschung mbH

Probiodrug is part of the new biocenter in Halle/Saale, Germany. The company was founded in September 1997 with the aim to identify and develop new classes of drugs; small molecules, that modulate the activity of proline-specific peptidases. These proline specific peptidases are involved in the following human diseases: Diabetes, Dementia, Adipositas. The objectives of Probiodrug are to investigate the mechanisms of interactions between proline-specific peptidases and their effectors. The acquired knowledge will be used to develop specific inhibitors for this particular family of enzymes as potential drugs.

Activity:

- Research & Development

Product / Technology type(s) covered:

- Bio
- Enzymes
- Pharmaceuticals / Therapeutics

Therapeutic targets:

Markets Covered

a. HeadQuarter:

b. Continent(s) active:

c. Countries active:

Corporate data:

Number of Employees:

Turnover:

Amount:	Year:	Currency:

Year founded: